Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00177463 · ClinicalTrials.gov registry record · NA

L-Carnosine for Bipolar I Disorder

A NA study, sponsored by University of Pittsburgh.

Completed
Registry status
NA
Development phase
47
Enrollment target

NCT00177463 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00177463, a NA study, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target

Study Summary

Our hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial ability and language) in persons with bipolar disorder. Secondarily, we hypothesize there will be secondary improvements in positive, negative and mood symptoms with L-carnosine treatment. We aim to test these hypotheses by conducting a randomized, placebo controlled, add on treatment trial of L-carnosine (added to existing antipsychotic treatment) on 48 recruited subjects with DSM IV TR bipolar disorder for a period of 12 weeks. Measures of cognition, and psychopathology will be utilized for evaluating primary and secondary outcomes, along with safety assessments.

Interventions

  • DRUG L-carnosine

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2004-09
Est. Completion 2007-12
Phase NA

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT00177463

The ClinicalTrials.gov registry entry for NCT00177463 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which L-carnosine is the first listed.

NCT00177463 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00177463 about?

NCT00177463 is a clinical study titled "L-Carnosine for Bipolar I Disorder". Our hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial ability and language) in persons with bipolar disorder. Secondarily, we hypothesize there will be secon...

What is the current status of trial NCT00177463?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2004-09. Estimated completion is 2007-12.

What interventions are being tested in trial NCT00177463?

The interventions under investigation include: L-carnosine (DRUG).

Who is sponsoring clinical trial NCT00177463?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.